Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma: Should Vein Abutment Matter?
In this largest cohort to date of patients with upfront resectable PDAC, PMV abutment was associated with worse OS compared with no PMV abutment when an upfront resection strategy was used. The use of NAT in patients with PMV abutment mitigated this survival difference with increased R0 resection rates. These findings suggest that patients with upfront resectable PDAC with PMV abutment benefit from a NAT approach for optimal survival outcomes, and that the current criteria guidelines need to be redefined.
Authors
- Po Hong Tan
- M. Truty
- Katherine E. Poruk (ORCID: https://orcid.org/0000-0002-2170-1688)
- Michelle R. Huyser
- R. Smoot
- M. Kendrick
- Richard J. Bold (ORCID: https://orcid.org/0000-0003-1181-1573)
- R. Miller
- Melody Pi Yin Tu
- Hoe Yan Hor
- Cornelius A. Thiels
- _ _
- Chee-Chee Stucky
- Nabil Wasif
- John A. Stauffer
- Susanne G. Warner
- Patrick P. Starlinger
Institutions
- WinnMed (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2026-02-01
- DOI
- https://doi.org/10.6004/jnccn.2025.7097
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00